Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03286335 · ClinicalTrials.gov registry record · NA
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
A NA study of Brain Tumor, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- NA
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03286335: Recruiting NA study of Brain Tumor, sponsored by Massachusetts General Hospital.
NCT03286335 is a NA study of Brain Tumor that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 100 participants, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03286335, a NA study of Brain Tumor, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- NA
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying Proton Radiation as a possible treatment for brain tumor. The radiation involved in this study is: -Proton Radiation
Primary Outcome
The duration of local control will be measured from the start date of protocol radiation until the date of progressive disease. Local control is defined as the lack of tumor growth as determined by a brain MRI (magnetic resonance imaging). This will include tumors that appear unchanged in size as compared to the baseline pre-radiation scan and also tumors that appear slightly reduced in size as may occur in response to radiation therapy. Inflammation secondary to radiation therapy can radiograph
Conditions Studied
Interventions
- RADIATION Proton Radiation
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-09-26 |
| Est. Completion | 2027-09-30 |
| Phase | NA |
What NCT03286335 shows while recruiting
NCT03286335 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 280-participant average among 69 other Brain Tumor trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which Proton Radiation is the first listed.
NCT03286335 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03286335 about?
NCT03286335 is a clinical study titled "Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy". This research study is studying Proton Radiation as a possible treatment for brain tumor. The radiation involved in this study is: -Proton Radiation
What is the current status of trial NCT03286335?
This trial is currently recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2018-09-26. Estimated completion is 2027-09-30.
What conditions does trial NCT03286335 study?
This clinical trial studies the following conditions: Brain Tumor.
What interventions are being tested in trial NCT03286335?
The interventions under investigation include: Proton Radiation (RADIATION).
Who is sponsoring clinical trial NCT03286335?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03286335 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03286335's enrollment target sits among peer trials
100 18th of 69 higher than 51 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Cognitive Training in the Virtual Reality Setting With Children Undergoing Radiotherapy for Brain Tumors
RECRUITING · NA
-
Extracellular Impact of Ultrasound-induced Blood-brain Barrier Disruption
RECRUITING · NA
-
Ommaya Reservoir Placement for Brain Tumor Biomarker Access
RECRUITING · NA
-
Mapping of Human Cognition
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI